Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een fase 2b klinische studie van YN001 bij volwassenen met coronaire atherosclerose (PURIFY-TIMI 81)

3 november 2026 bijgewerkt door: Beijing Inno Medicine Co., Ltd.

Een gerandomiseerde, multicenter, dubbelblinde, parallelle, placebo-gecontroleerde fase 2b klinische studie om de werkzaamheid en veiligheid van YN001 bij volwassenen met coronaire atherosclerose te evalueren

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are receiving background therapy for cardiovascular (CV) risk factors management.

Studie Overzicht

Gedetailleerde beschrijving

This is a multinational, multicenter, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of intravenously administered YN001 compared with placebo in participants with coronary atherosclerosis who are receiving background therapy for CV risk factors management.

A total of 456 participants are expected to be enrolled. The study will consist of a maximum 12-week screening/Baseline period, followed by a 12-week blinded treatment period, a 30-day safety follow-up, and a long-term follow-up period through Week 96 (approximately 2 years after randomization).

Studietype

Ingrijpend

Inschrijving (Geschat)

456

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • New South Wales
      • Penrith, New South Wales, Australië, 2750
        • Werving
        • Cannopy Clinical Research
        • Contact:
    • Queensland
      • Brisbane, Queensland, Australië, 4064
        • Werving
        • Core Research Group Pty Ltd.
        • Contact:
    • Victoria
      • Altona N., Victoria, Australië, 3025
        • Werving
        • Canopy Clinical Research
        • Contact:
    • Manitoba
      • Winnipeg, Manitoba, Canada, R2H 2A6
        • Nog niet aan het werven
        • St. Boniface Hospital
        • Contact:
    • Ontario
      • London, Ontario, Canada, N5A 5A5
        • Nog niet aan het werven
        • London Health Sciences Centre
        • Contact:
      • North York, Ontario, Canada, M6B 3H7
        • Nog niet aan het werven
        • North York Diagnostic and Cardiac Centre
        • Contact:
      • Toronto, Ontario, Canada, M5B 1W8
        • Nog niet aan het werven
        • St. Michael's Hospital
        • Contact:
      • Vaughan, Ontario, Canada, L6A 4N9
        • Nog niet aan het werven
        • Cardiac Clinic
        • Contact:
    • Toronto
      • Toronto, Toronto, Canada, M5G 2N2
        • Nog niet aan het werven
        • Toronto General Hospital - University Health Network
        • Contact:
    • An
      • Hefei, An, China, 230022
        • Werving
        • The First Affiliated Hospital of Anhui Medical Unversity
        • Contact:
          • Jianlong Wang, MD
          • Telefoonnummer: 0086-13681292304
          • E-mail: Wjlmll@sina.com
    • Anhui
      • Hefei, Anhui, China, 230001
        • Werving
        • Anhui Provincial Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Kangyu Chen, MD
        • Onderonderzoeker:
          • Chao Gao, MD
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100035
        • Werving
        • Beijing Jishuitan Hospital
        • Hoofdonderzoeker:
          • Wei Liu, MD
        • Contact:
          • Qingwei Ji, MD
          • Telefoonnummer: 0086 18376642655
          • E-mail: jqwl24@163.cou
        • Hoofdonderzoeker:
          • Qingwei Ji, MD
      • Beijing, Beijing Municipality, China, 100029
        • Werving
        • Anzhen Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Yuyang Liu, MD
      • Beijing, Beijing Municipality, China, 101100
        • Nog niet aan het werven
        • Beijing Luhe Hospital
        • Contact:
    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Werving
        • Fujian Medical University Union Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Mingfang Ye, MD
        • Onderonderzoeker:
          • Zhaoyang Chen, MD
    • Gansu
      • Lanzhou, Gansu, China, 730030
        • Werving
        • The Second Hospital & Clinical Medical School Lanzhou University
        • Contact:
    • Guangdong
      • Guangzhou, Guangdong, China, 510080
    • Heilongjiang
      • Daqing, Heilongjiang, China, 163316
        • Werving
        • Daqing People's Hospital
        • Contact:
      • Harbin, Heilongjiang, China, 150001
        • Werving
        • The First Affiliated Hospital of Harbin Medical University
        • Contact:
        • Hoofdonderzoeker:
          • Lu Fu, MD
        • Hoofdonderzoeker:
          • Yongtai Gong, MD
    • Hubei
      • Wuhan, Hubei, China, 430071
        • Werving
        • Zhongnan Hospital of Wuhan University
        • Contact:
        • Hoofdonderzoeker:
          • Xiaorong Hu, MD
    • Hunan
      • Changsha, Hunan, China, 410008
        • Werving
        • The Second Xiangya Hospital fo Central South University
        • Contact:
    • Jilin
      • Changchun, Jilin, China, 130033
        • Werving
        • The First Hospital of Jilin University
        • Hoofdonderzoeker:
          • Qian Tong, MD
        • Contact:
    • Liaoning
      • Shenyang, Liaoning, China, 110015
        • Werving
        • The People's Hospital of Liaoning Province
        • Hoofdonderzoeker:
          • Ying Liu, MD
        • Contact:
    • Shaanxi
      • Xi'an, Shaanxi, China, 710068
        • Werving
        • Shaanxi Provincial People's Hospital
        • Contact:
    • Shandong
      • Jinan, Shandong, China
        • Werving
        • Central Hospital Affiliated to Shandong First Medicial University
        • Contact:
          • Guohai Su, MD
          • Telefoonnummer: 0086 19953193319
          • E-mail: gttstg@163.com
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Werving
        • Fudan University-Zhongshan Hospital
        • Hoofdonderzoeker:
          • Junbo Ge, MD
        • Contact:
        • Onderonderzoeker:
          • Yuxiang Dai, MD
      • Shanghai, Shanghai Municipality, China, 200001
        • Werving
        • Renji Hospital Shanghai Jiaotong University school of medicine
        • Contact:
        • Hoofdonderzoeker:
          • Jun Bu, MD
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Werving
        • West China Hospital of Sichuan University
        • Contact:
        • Hoofdonderzoeker:
          • Yong He, MD
      • Chengdu, Sichuan, China, 610072
        • Werving
        • Sichuan Provincial People's Hospital
        • Contact:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300211
        • Werving
        • The Second Hospital of Tianjin Medical University
        • Contact:
        • Hoofdonderzoeker:
          • Tong Liu, MD
      • Tianjin, Tianjin Municipality, China, 300121
        • Werving
        • Tianjin People's Hospital
        • Hoofdonderzoeker:
          • Zhuhua Yao, MD
        • Contact:
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310006
        • Werving
        • Zhejiang Provincial People's Hospital
        • Contact:
      • Suzhou, Zhejiang, China, 215006
        • Werving
        • The First Affiliated Hospital of Soochow University
        • Contact:
      • Wenzhou, Zhejiang, China, 325000
        • Werving
        • The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU
        • Contact:
    • Alabama
      • Huntsville, Alabama, Verenigde Staten, 35801-4312
        • Werving
        • Heart Center Research, LLC
        • Contact:
    • California
      • Covina, California, Verenigde Staten, 91740
      • Lincoln, California, Verenigde Staten, 95648
        • Nog niet aan het werven
        • Clinical Trials Research
        • Contact:
      • Los Alamitos, California, Verenigde Staten, 90720
        • Nog niet aan het werven
        • University of California Irvine Medical Center - Cardiovascular Center
        • Contact:
      • Stanford, California, Verenigde Staten, 94305-2200
        • Nog niet aan het werven
        • Stanford Health Care General Cardiology
        • Contact:
      • Torrance, California, Verenigde Staten, 90502-2006
        • Werving
        • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
        • Contact:
    • Florida
      • Boca Raton, Florida, Verenigde Staten, 33434
        • Nog niet aan het werven
        • Flourish Research - Boca Raton
        • Contact:
      • Hialeah, Florida, Verenigde Staten, 33016-1895
        • Werving
        • New Generation of Medical Research, LLC.
        • Contact:
      • St. Petersburg, Florida, Verenigde Staten, 33709
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30303-3049
        • Nog niet aan het werven
        • Emory Healthcare-Emory Heart & Vascular Center - Executive Park
        • Contact:
    • Idaho
      • Meridian, Idaho, Verenigde Staten, 83642
        • Nog niet aan het werven
        • St. Luke's Clinic - Idaho Cardiology Associates
        • Contact:
    • Illinois
      • Springfield, Illinois, Verenigde Staten, 62781
        • Nog niet aan het werven
        • Southern Illinois University School of Medicine
        • Contact:
    • Kansas
      • Overland Park, Kansas, Verenigde Staten, 66211-1215
        • Werving
        • Midwest Heart & Vascular Specialists, LLC
        • Contact:
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63110-1032
        • Werving
        • WU School of Medicine - (CAM) - Heart and Vascular Center
        • Contact:
    • North Carolina
      • Raleigh, North Carolina, Verenigde Staten, 27607
        • Nog niet aan het werven
        • NC Heart and Vascular Research, LLC
        • Contact:
      • Winston-Salem, North Carolina, Verenigde Staten, 27104-3520
        • Nog niet aan het werven
        • Javara Inc. - Wake Forest University Health Sciences
        • Contact:
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45219
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73135
        • Nog niet aan het werven
        • South Oklahoma Heart Research, LLC
        • Contact:
    • Pennsylvania
      • Camp Hill, Pennsylvania, Verenigde Staten, 17011
        • Werving
        • Capital Area Research, LLC - Camp Hill
        • Contact:
    • Texas
      • Amarillo, Texas, Verenigde Staten, 79106
        • Werving
        • PharmaTex Research, LLC
        • Contact:
      • Carrollton, Texas, Verenigde Staten, 75010
        • Nog niet aan het werven
        • Pulse Care Heart and Vascular
        • Contact:
      • Tomball, Texas, Verenigde Staten, 77375
        • Nog niet aan het werven
        • DM Clinical Research - Dallas
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Fully understands the purposes, features, and methods of the study and the possible adverse reactions, and is voluntarily willing to participate in the study, and signs the informed consent form (ICF) before performing any study-specific assessment.
  2. Male or female participants between 18 and 80 years (inclusive, at the time of signing the ICF).
  3. Participants must satisfy either of the following criteria:

1) Have clinically evident atherosclerotic CV disease (ASCVD) 2) Meet at least two of the following criteria at screening/baseline, as evidenced by:

  1. A history of Type 2 diabetes requiring treatment with medication,

  2. Aged > 55 years (women) or > 50 years (men),

  3. 2 or more of the following atherosclerosis risk factors:

    • Current cigarette smoker

    • Hypertension

    • Estimated glomerular filtration rate (eGFR) 45 to 60 ml/min/1.73m2

      4. Known coronary atherosclerosis as evidenced through coronary angiography or CCTA. The following criteria must be met on the core lab CCTA interpretation for the patient to be enrolled: at least one epicardial coronary artery with a lumen stenosis of 25% to 69%, total coronary NCPV is at least 75 mm3, Detectable low-attenuation composition in one or more individual plaques.

      5. Female participants must be non-pregnant and non-lactating

      6. Willing and able to comply with the requirements of protocol to the best of the participant's and investigator's knowledge.

Exclusion Criteria:

  1. Prior treatment with other investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization, or any planned vaccination during the study treatment period
  4. Contraindication for CCTA
  5. 3 major epicardial coronary arteries with ≥ 70% or left main ≥50% stenosis.
  6. Acute MI that occurred within 4 weeks prior to randomization.
  7. PCI performed within 2 weeks prior to randomization or PCI is required or planned during study treatment based on clinical indication for revascularization.
  8. Clinically evident stroke or transient ischemic attack (TIA) within 6 months prior to randomization.
  9. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months.
  10. Prior coronary artery bypass graft (CABG), aortic root surgery with coronary reimplantation, left ventricular assist device (LVAD) placement, surgical aortic valve replacement (SAVR), transcatheter aortic valve replacement (TAVR), or heart transplantation, or a plan to undergo these procedures (CABG, aortic root surgery with coronary reimplantation, LVAD placement, SAVR, TAVR, or heart transplantation) during the study.
  11. New York Heart Association class III or IV or last known left ventricular ejection fraction (LVEF) was <40%.
  12. Carotid endarterectomy or stenting, peripheral arterial revascularization, or abdominal aortic aneurysm repair within 4 weeks prior to randomization.
  13. History of myopathy or myositis, or susceptibility to myopathy/rhabdomyolysis (e.g., family history of hereditary myopathy, etc.).
  14. History of severe myalgia attributed to statin therapy or other significant concern about statin side effects.
  15. Known gastrointestinal ulcers, inflammatory bowel disease, or gastrointestinal/rectal bleeding within 6 months prior to randomization.
  16. Evidence of unresolved major diseases 2 weeks prior to randomization or planned major surgery during the study that, in the investigator's judgement, may interfere with the investigational product administration or trial assessments.
  17. Presenting with history of malignancy (except in participants who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  18. Presence of any type of autoimmune disease.
  19. Allergy to multiple foods or drugs or known sensitivity to any components to be administered during dosing.
  20. Life expectancy is less than 1 year.
  21. Systolic blood pressure of ≥ 160 mmHg at final screening despite antihypertensive therapy.
  22. Triglycerides ≥ 400 mg/dL (4.5 mmol/L) at final screening.
  23. LDL-C > 100 mg/dL (2.6 mmol/L) at final screening.
  24. Active liver disease or hepatic dysfunction defined by any of alanine aminotransaminase (ALT), aspartate aminotransferase (AST), > 3 times upper limit of normal (ULN), or total bilirubin > 2 times ULN at final screening.
  25. Presence of renal dysfunction, defined by eGFR < 45 ml/min/1.73m2.
  26. Untreated or inadequately treated hypothyroidism.
  27. Poorly controlled Type 2 diabetes mellitus.
  28. A positive hepatitis B surface antigen (HBsAg), or positive antibody against hepatitis C virus (anti-HCV) or human immunodeficiency virus (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  29. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the participant to participate in this study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Dose 1 YN001/Placebo 40mg

Dose 1 YN001/Placobo 40mg will be administrated intravenously weekly

Dose 1 YN001/Placebo 40mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Experimenteel: Dose 2 YN001/Placebo 20mg

Dose 2 YN001/Placebo 20mg will be administrated intravenously weekly

YN001/Placebo 20mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Placebo-vergelijker: Dose 3 YN001/Placebo 0mg

Dose 3 YN001/Placebo 0mg will be administrated intravenously weekly

YN001/Placebo 0mg will be administrated on Day 1 of each week from Week 1 to Week 13, 13 times in total.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Relative change from baseline in coronary NCPV at Week 13
Tijdsspanne: Baseline to Week 13

Relative change in coronary NCPV from baseline to Week 13 as determined by coronary computed tomography angiography (CCTA)

Baseline to Week 13

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 13
Tijdsspanne: From baseline to Week 13

Absolute change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound.

From baseline to Week 13
Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9
Tijdsspanne: From baseline to Week 9

Absolute change from baseline in carotid intima-media thickness (IMT) at Week 9

From baseline to Week 9
Relative change from baseline in carotid intima-media thickness (IMT) at Week 13
Tijdsspanne: From baseline to Week 13

Relative change in carotid IMT from baseline to Week 13 as determined by carotid ultrasound

From baseline to Week 13
Relative change in the maximum thickness and area of carotid plaque at Week 9, and Week 13
Tijdsspanne: From baseline to Week 9 and Week 13

Relative change in the maximum thickness and area of carotid plaque from baseline to Week 9, and Week 13 as determined by carotid ultrasound

From baseline to Week 9 and Week 13
Relative change in coronary Percent Atheroma Volume (PAV) at Week 13
Tijdsspanne: From baseline to Week 13

Relative change in coronary Percent Atheroma Volume (PAV) from baseline to Week 13 as determined by CCTA

From baseline to Week 13
Relative change in coronary Low Attenuation Plaque Volume(LAPV) at Week 13
Tijdsspanne: From baseline to week 13

Relative change in coronary LAPV from baseline to Week 13 as determined by CCTA.

From baseline to week 13
Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline at 48 week
Tijdsspanne: From baseline to week 48

Relative changes in coronary NCPV, PAV, TAV, and LAPV from baseline to Week 48 as determined by CCTA

From baseline to week 48
Absolute change in coronary NCPV at week 13 and week 48
Tijdsspanne: From baseline to week 13 and week 48

Absolute change in coronary NCPV from baseline to Week 13 and Week 48 as determined by CCTA

From baseline to week 13 and week 48
Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)
Tijdsspanne: From randomization to Week 96

Time to the first occurrence of the MACE, composite of CV death, myocardial infarction (MI), ischemic stroke, urgent coronary revascularization, or hospitalization for unstable angina

From randomization to Week 96
The safety profile of YN001
Tijdsspanne: From baseline to Week 13

Incidence of treatment emergent adverse event (TEAE)/serious adverse event (SAE)/adverse event of special interest (AESI)

From baseline to Week 13
Immunogenicity (ADA) analysis
Tijdsspanne: From baseline to Week 13

Incidence of anti-drug antibodies (ADA) formation

From baseline to Week 13
Immunogenicity (APA) analysis
Tijdsspanne: From baseline to Week 17

Incidence of anti-PEG antibodies (APA) formation

From baseline to Week 17
YN001 concentrations analysis in plasma
Tijdsspanne: From baseline to Week 13

Sparse blood samples will be collected, and these concentrations are intended to be pooled with other studies to develop/update pharmacometric models

From baseline to Week 13

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Medewerkers

Onderzoekers

  • Studie directeur: Ying Chen, PhD, Beijing Inno Medicine Co., Ltd.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

31 juli 2026

Primaire voltooiing (Geschat)

31 juli 2027

Studie voltooiing (Geschat)

31 maart 2029

Studieregistratiedata

Eerst ingediend

2 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

2 april 2026

Eerst geplaatst (Werkelijk)

9 april 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 november 2026

Laatste update ingediend die voldeed aan QC-criteria

3 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • YN001-203
  • IND 157167 (Register-ID: Beijing Inno Medicine Co., Ltd.)

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren